Vivos Therapeutics Inc (VVOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has a cash flow conversion efficiency ratio of 4.743x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.01 Million) by net assets ($-1.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VVOS equity financing ratio to measure how much of total assets are equity-financed.
Vivos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore VVOS operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Vivos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanwha Corp. Pfd. Series 1
KO:000885
|
0.114x |
|
Shiva Mills Limited
NSE:SHIVAMILLS
|
0.061x |
|
tokentus investment AG
MU:14D
|
N/A |
|
Lithium Universe Ltd
AU:LU7
|
1.359x |
|
Canadian Premium Sand Inc
V:CPS
|
0.097x |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
0.035x |
|
ICDS Limited
NSE:ICDSLTD
|
0.021x |
|
E Investment & Development
KO:093230
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see VVOS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.55 Million | $-15.26 Million | 9.847x | +717.16% |
| 2024-12-31 | $7.95 Million | $-12.69 Million | -1.596x | +94.51% |
| 2023-12-31 | $411.00K | $-11.95 Million | -29.066x | -612.43% |
| 2022-12-31 | $4.80 Million | $-19.59 Million | -4.080x | -562.18% |
| 2021-12-31 | $25.54 Million | $-15.73 Million | -0.616x | -83.50% |
| 2020-12-31 | $16.92 Million | $-5.68 Million | -0.336x | -118.50% |
| 2019-12-31 | $-2.94 Million | $-5.34 Million | 1.815x | +264.83% |
| 2018-12-31 | $4.83 Million | $-5.31 Million | -1.101x | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more